Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Kidney Int. 2016 Dec 22;91(3):711–719. doi: 10.1016/j.kint.2016.10.021

Figure 2. Additive effects of elevated levels of inflammatory markers and FGF23 on risk of mortality.

Figure 2

Figure 2

(A) Crude mortality rates according to combined quartiles of IL-6 and FGF23.

(B) Crude mortality rates according to a baseline quartiles of CRP and FGF23